Preclinical and clinical studies on immunogenicity and safety of the HIV-1 p17-based synthetic peptide AIDS vaccine — HGP-30-KLH
Paul H. Naylor(Wayne State University), Allan L. Goldstein(George Washington University), Scott H. Maurer(University of Pittsburgh), Daniel Zagury(Sorbonne Université), Saiji Wada(Washington University Medical Center), Marcelo B. Sztein(University of Maryland, Baltimore), Brian Gazzard(Chelsea and Westminster Hospital NHS Foundation Trust), Bernard C. Zook(Washington University Medical Center), Janet E. Kirkley(Washington University Medical Center), Cartha W. Naulor(Washington University Medical Center), Ammar Achour(Sorbonne Université), Prem S. Sarin(National Institutes of Health), Carol O’Toole(University of London), Adan Rios(Oaks Hospital), Clarence J. Gibbs, Richard A. Hitzelberg(Washington University Medical Center), Mike Youle(The Royal Free Hospital), Daniel A. Holterman(Caris Life Sciences (United States))
Cited by 31
Related Papers
Long-Term Cultures of HTLV-III—Infected T Cells: a Model of Cytopathology of T-Cell Depletion in AIDS
|Science|1986|535
Serum Levels of the Proinflammatory Cytokines Interleukin-1 Beta (IL-1β), IL-6, IL-8, IL-10, Tumor Necrosis Factor Alpha, and IL-12(p70) in Malian Children with Severe<i>Plasmodium falciparum</i>Malaria and Matched Uncomplicated Malaria or Healthy Controls
|Infection and Immunity|2004|447
Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road
|Nature Reviews Microbiology|2007|372
HTLV-III in Cells Cultured from Semen of Two Patients with AIDS
|Science|1984|318
Safety of live oral Salmonella typhi vaccine strains with deletions in htrA and aroC aroD and immune response in humans
|Infection and Immunity|1997|251